Exelixis Inc (EXEL)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $16.84B
Last updated: Nov 17, 2026 at 11:05 AM ET
Exelixis Inc (EXEL) Stock Forecast
Analysts expect Exelixis (EXEL) to earn $3.75 per share in the fiscal year ending Dec 31, 2026, on revenue of $2.56B. Of 17 analysts, 6 rate the stock Buy or Strong Buy, 10 Hold and 1 Sell or Strong Sell, for a consensus of Hold. Over the last 30 days, 6 estimates for the fiscal year ending Dec 31, 2026 were revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 17 ratings average 2.71, inside the Hold band from 2.5 up to 3.5. Buy and Strong Buy make up 35% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 5.9% |
| Buy | 5 | 29.4% |
| Hold | 10 | 58.8% |
| Sell | 0 | 0.0% |
| Strong Sell | 1 | 5.9% |
- Consensus
- Hold
- Total analysts
- 17
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 13.9% and revenue estimates rise 12.5%.
- Fiscal year ending Dec 31, 2026
- $3.75
- EPS consensus, revenue $2.56B
- Fiscal year ending Dec 31, 2027
- $4.27
- EPS consensus, revenue $2.88B
- Next report
- Feb 8, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $3.75 | $3.49 to $3.94 | 9 | $2.56B | $2.53B to $2.59B | 15 |
| Dec 31, 2027 | $4.27 | $3.44 to $5.34 | 9 | $2.88B | $2.54B to $3.05B | 15 |
Quarterly Estimates
The EPS consensus falls from $1.00 for the quarter ending Dec 31, 2026 to $0.88 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $1.00 | $0.77 to $1.23 | 19 | $672.09M | $625.53M to $721.35M | 17 |
| Mar 31, 2027 | $0.88 | $0.82 to $0.94 | 2 | $690.77M | $670.00M to $722.13M | 4 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 12 upward and 1 downward EPS revisions. Raises outnumber cuts in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 6 | 0 |
| Fiscal year ending Dec 31, 2027 | 5 | 1 |
| Quarter ending Mar 31, 2027 | 1 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 5.9% from $3.54.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $3.75 | $3.58 | $3.59 | $3.58 | $3.54 | +6.1% |
| Fiscal year ending Dec 31, 2027 | $4.27 | $4.27 | $4.26 | $4.26 | $4.05 | +5.6% |
| Quarter ending Mar 31, 2027 | $0.88 | $0.94 | $0.94 | $0.97 | $0.94 | -6.3% |
Frequently Asked Questions About EXEL
What is the EXEL stock forecast?
Consensus analyst estimates put Exelixis's EPS at $3.75 for the fiscal year ending Dec 31, 2026, on revenue of $2.56B. The consensus rating from 17 analysts is Hold.
How do analysts rate EXEL stock?
Of 17 analysts covering Exelixis, 1 rates it Strong Buy, 5 Buy, 10 Hold, 0 Sell and 1 Strong Sell, for a consensus of Hold.
What EPS do analysts expect from EXEL next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $3.75, with estimates from $3.49 to $3.94 from 9 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $4.27, with estimates from $3.44 to $5.34 from 9 analysts.
What revenue do analysts expect from Exelixis next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $2.56B, with estimates from $2.53B to $2.59B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $2.88B, with estimates from $2.54B to $3.05B.
How many analysts cover EXEL?
17 analysts rate Exelixis stock, and 9 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
EXEL pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors